MIB Agents OsteoBites and osTEAo

MIB Agents OsteoBites and osTEAo

By MIB Agents OsteosarcomaMedicineHealth & Fitness
Download on the App Store

MIB Agents OsteoBites and osTEAo episodes

  • osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma

    Camille and Mia are joined by OsteoWarriors Jasmine, Penelope and Walker to share their experiences with local control strategies to remove osteosarcoma lung metastasis, including surgery, radiation therapy, and cryoablation. They cover everything from their reaction to hearing they needed a lung surgery, how they prepared for surgery - both mentally and pro tips for how to make yourself comfortable in the hospital, managing their pain and nausea post surgery, recovery time for the different types of procedures, and their individual outcomes post procedure. In addition to hearing about their personal experiences, you'll learn about the power of escapism TV, why a spirometer can be scary, the wonders of a Da Vinci robot, and the technical term for stabby-stabby, freezy-freezy

    1 hr 17 min
  • Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research

    Donghan “Mo” Yang, PhD, is a researcher in the field of data science and health informatics.  He joins us on OsteoBites to introduce the development of the Osteosarcoma Explorer (OSE), a data commons with clinical, genomic, protein, and tissue imaging data for osteosarcoma research. The OSE is one of the flagship projects cultivated within the CPRIT-funded Pediatric Cancer Data Core (Director: Yang Xie, PhD, Professor and Associate Dean of Data Science, UT Southwestern). The goal of the OSE project is to integrate publicly available and institutional osteosarcoma data of various types and share them with the research community via an interactive web interface. The OSE web portal is now accessible to the public at https://datacommons.swmed.edu/cce/ose.Dr. Yang is an Assistant Professor and a Texas Health Resources Clinical Scholar in the Quantitative Biomedical Research Center at Peter O’Donnell Jr. School of Public Health, UT Southwestern Medical Center. He also serves as the Director of Biostatistics and Data Science Core at UT Southwestern. Dr. Yang’s research focuses on developing methods, platforms, and infrastructure for the management, integration, and analysis of real-world healthcare data, including electronic health records, imaging, and molecular profiling data. He has led team efforts of building data commons – comprehensive database interfaced by user-friendly web portal – for adult and childhood cancers and other diseases. He also applies advanced analytics to gain insights from these real-world data resources.

    1 hr 5 min
  • Patient perspectives on participating in research and clinical trials

    Jennifer Mack, MD, MPH from Dana-Farber Cancer Institute/Boston Children’s and Harvard Medical School join us on OsteoBites to discuss best practices for engaging patients in research and clinical trials. Dr. Mack is also part of the PE-CGS Network (Participant Engagement and Cancer Genome Sequencing) Count Me In Research Center team and she will be discussing reasons that patients may or may not want to participate in research, ways to engage patients in designing and carrying out trials., and Count Me In as one model for engaging patients.Dr. Mack received her medical degree from Harvard Medical School in 1998. She subsequently completed her residency in Pediatrics and her fellowship in Pediatric Hematology Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute in Boston, MA. In 2005, Dr. Mack received a Master’s Degree in Public Health from the Harvard School of Public Health. She is an attending physician at Dana-Farber Cancer Institute and Boston Children's Hospital, Director of the Center for Outcomes and Policy Research at Dana-Farber, Associate Chief of the Division of Population Sciences at Dana-Farber, Associate Chief for Pediatric Oncology Population Sciences at Dana-Farber/Boston Children’s, and Faculty Vice President for the Office for Faculty Development, Professionalism, and Inclusion at Dana-Farber. She is also an Associate Professor of Pediatrics at Harvard Medical School. Her research interests are in parent-clinician and patient-clinician communication, health care equity and quality, and palliative care.

    1 hr 3 min
  • Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery

    Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O’Connor Starter Scholar Research Award, etc.

    1 hr 5 min
  • Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

    Dr. David Shulman is a pediatric oncologist at Dana-Farber Cancer Institute. He studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas. He joins us on OsteoBites to discuss the LEOPARD Study: Liquid Biopsy in Ewing sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic

    1 hr 2 min
  • Managing Stress in AYA Cancer Patients

    A cancer diagnosis and the treatment that follows can trigger stress and anxiety. Camille is joined this week by Dr. Abby Rosenberg, an expert in helping AYA cancer patients manage stress. They chat about why being diagnosed as an adolescent/young adult has particular challenges, tools and techniques for managing stress, and how palliative care is different from hospice care (spoiler alert - it's not just for end of life care!). Listen in to learn why stress is normal, the three categories of resilience resources, the power of distraction, the benefit of emotions, and how palliative care helps the entire care team focus on what is important to the patient. Abby R. Rosenberg, MD, MS, MA, joined the team at Boston Children's Hospital as the Director of Palliative Care in 2023. She is also the Chief of Pediatric Palliative Care at the Dana-Farber Cancer Institute. Prior to that, she was at the University of Washington and Seattle Children’s Hospital, where she served as the Director of Survivorship and Outcomes Research and Director of Pediatrics at the Cambia Palliative Care Center of Excellence. Both Dr. Rosenberg’s clinical approach and her research focus on helping people facing serious illness to live their best lives, for as long as possible. Specifically, she and her team develop programs that help patients and families build resilience and optimize their quality of life.

    38 min
  • Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

    David Freyer, DO, MS provides a review of hearing loss as a serious and permanent side effect caused by cisplatin chemotherapy, recent research regarding its prevention, and its relevance for young people treated for osteosarcoma.David R. Freyer, DO, MS is Professor of Clinical Pediatrics, Medicine, and Population and Public Health Sciences at the Keck School of Medicine, University of Southern California. He currently serves as Director of the Survivorship and Supportive Care Program in the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles, and as Director of the Cancer Survivorship Program and Co-Director of the Adolescent and Young Adult Cancer Program, both at the USC Norris Comprehensive Cancer Center. Dr. Freyer’s clinical care and research are concentrated in cancer survivorship, cancer control/supportive care, and AYA oncology with interests in treatment-related toxicity, survivorship care transition, cancer care disparities, and patient-reported outcomes. He had the privilege of leading ACCL0431, a randomized Children's Oncology Group study and pivotal trial leading to FDA approval of sodium thiosulfate as the first proven agent to prevent cisplatin-induced hearing loss in young people treated for cancer.

    1 hr 1 min
  • TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma

    Dr. Andy Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology, and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. Dr. Livingston joins us on OsteoBites to discuss the background and scientific rationale for combining immunotherapy with cabozantinib in teens and young adults with osteosarcoma and provide information about the ongoing TACOS study: Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma.Dr. Livingston is a clinician and researcher in Sarcoma Medical Oncology and holds a joint appointment in Pediatric Oncology at MD Anderson Cancer Center in Houston, Texas. After completing medical school at the University of Texas Medical Branch at Galveston, he went on to residency training at Duke University where he completed a combined residency in internal medicine and pediatrics. Dr. Livingston completed his fellowship training at MD Anderson where he served as the Chief Fellow for Hematology/Oncology Fellowship Program. Dr. Livingston has a particular interest in the care of teens and young adults with cancer and is Co-director of the MD Anderson Adolescent and Young Adult (AYA) oncology program. His clinical and translational research is focused on developing new treatment strategies for patients with osteosarcoma and other bone sarcomas. He received the MIB OutSmarting Osteosarcoma award in 2020 for his work on the immune landscape of osteosarcoma and serves as a member of the MIB Scientific Advisory Board.

    1 hr
  • osTEAo: Making friends after a cancer diagnosis

    Camille and Mia kick off Season 3 of osTEAo with a chat on friendships after a cancer diagnosis. With special guest Vicky, MIB Agents 2023 Junior Advisory Board president, Camille and Mia discuss how to rebuild a life with meaningful connections and friendships when treatment removes you from school, your sports and extracurricular activities, and seeing your friends everyday. In this frank and sometimes hilarious discussion, you'll hear about the shift from quality to quantity, the positive effects of "opposite action", the value of long distance relationships, and the beauty of mocktails and staying in.

    48 min
  • Interventions to promote physical function during and after treatment for osteosarcoma

    Osteosarcoma Webinar Series: Keri Schadler, PhD and Kiri Ness, PT, PhD, FAPTA will partner to provide information about the importance of exercise for patients undergoing treatment as well as long term survivors of osteosarcoma. Together, they will provide a clinical perspective as well as an overview of the latest evidence that documents the need for and the initial success of exercise intervention during and after treatment for cancer.


    Dr. Schadler is an Associate Professor in the Department of Pediatrics at MD Anderson Cancer Center. Her lab utilizes mouse models and collaborations with clinical investigators to delineate the multi-faceted effects of exercise on the tumor microenvironment. Specifically, the Schadler lab aims to understand how exercise changes cellular and molecular signaling within the tumor vasculature and immune cells, and to use exercise as a tool to enhance tumor response to standard therapies.


    Dr. Ness is a physical therapist and clinical epidemiologist whose research focuses on the late effects of childhood and adolescent cancer and its treatment. She has a particular interest in human movement and performance, designing interventions to prevent functional loss during therapy or remediate impairment following curative treatment. She has over 350 peer reviewed original research papers and has had continuous funding to support her work since 2005. She is the MPI of the St. Jude Lifetime Cohort and PI of the Human Performance Laboratory at St. Jude Children's Research Hospital.

    1 hr 1 min

About MIB Agents OsteoBites and osTEAo

From the publisher's feed

Each week, MIB Agents talks with the leaders and innovators in osteosarcoma surgery, research, treatment and advocacy. Questions are taken during the webinar and are included in each podcast. More…

More shows like MIB Agents OsteoBites and osTEAo

The Deep C by Snack Labs

The Deep C

4 Listeners